PHILOGEN S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.1 EUR | +2.93% |
|
+0.48% | +14.05% |
| 06:00pm | Mib bullish ahead of ECB; STM and Nexi soar | AN |
| 12:14pm | Mib rises; ECB could push cyclical stocks up | AN |
| Sales 2024 * | 85.69M 93.17M | Sales 2025 * | 20.92M 22.75M | Capitalization | 826M 898M |
|---|---|---|---|---|---|
| Net income 2024 * | 3M 3.26M | Net income 2025 * | -46M -50.02M | EV / Sales 2024 * | 8.82 x |
| Net cash position 2024 * | 70.27M 76.4M | Net cash position 2025 * | 68.29M 74.25M | EV / Sales 2025 * | 36.2 x |
| P/E ratio 2024 * |
228
x | P/E ratio 2025 * |
-18
x | Employees | 165 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Philogen S.p.A.
More press releases
| 1 day | +2.93% | ||
| 1 week | +0.48% | ||
| Current month | -0.47% | ||
| 1 month | +17.55% | ||
| 3 months | +18.54% | ||
| 6 months | +17.88% | ||
| Current year | +14.05% |
1 week
20.20
21.60
1 month
17.6021.60
Current year
16.3021.60
1 year
14.9021.60
3 years
12.6021.60
5 years
12.6021.60
10 years
12.6021.60
| Managers | Title | Age | Since |
|---|---|---|---|
Dario Neri
CEO | Chief Executive Officer | 61 | 95-12-31 |
Duccio Neri
FOU | Founder | 61 | 95-12-31 |
Laura Baldi
DFI | Director of Finance/CFO | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | - | |
| Director/Board Member | 55 | - | |
Duccio Neri
FOU | Founder | 61 | 95-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 21.1 | +2.93% | 7 328 |
| 24-06-04 | 20.5 | -4.65% | 4,727 |
| 24-06-03 | 21.5 | +1.42% | 38,144 |
| 24-05-31 | 21.2 | +0.47% | 25,505 |
| 24-05-30 | 21.1 | +0.48% | 18,126 |
Real-time Borsa Italiana, June 05, 2024 at 11:44 am EDT
More quotes
Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.
Calendar
2024-06-07
- Chemical Biology Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
20.5
EUR
Average target price
23.5
EUR
Spread / Average Target
+14.63%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.05% | 899M | |
| +18.77% | 123B | |
| +14.58% | 107B | |
| -3.18% | 24.01B | |
| +2.18% | 22.59B | |
| -10.09% | 18.16B | |
| -41.04% | 16.84B | |
| -12.26% | 16.23B | |
| +1.80% | 13.43B | |
| +24.40% | 11.32B |
- Stock Market
- Equities
- PHIL Stock
